Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ImClone stock move on BLA plans

IMCLE was off $0.14 to $38.39 on 19.9 million shares despite reporting Thursday after

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE